Ono Pharmaceutical (OTCMKTS:OPHLF) Share Price Passes Above Fifty Day Moving Average - Here's Why

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $10.60 and traded as high as $12.58. Ono Pharmaceutical shares last traded at $11.50, with a volume of 781 shares.

Ono Pharmaceutical Price Performance

The company has a current ratio of 3.07, a quick ratio of 2.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $5.74 billion, a PE ratio of 19.71 and a beta of 0.51. The stock has a 50 day simple moving average of $10.69 and a 200-day simple moving average of $10.76.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by ($0.08). Ono Pharmaceutical had a return on equity of 5.49% and a net margin of 8.75%.The business had revenue of $886.27 million during the quarter, compared to analysts' expectations of $827.29 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.